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Abstract
Objectives We assessed if adjunct administration of piper-
acillin/tazobactam added clinical and microbiological treat-
ment benefits.
Materials and methods Thirty-six subjects (mean age 52.1
years (SD±10.3)) (NS by group) with chronic periodontitis
were randomly enrolled receiving subgingival debridement
and the local administration of piperacillin/tazobactam (test
group) or debridement alone (control group). Bleeding on
probing (BOP), probing pocket depth (PPD), and microbi-
ological counts of 74 species were studied by checkerboard
DNA-DNA hybridization up to month 6 after treatment.
Results >Mean PPD changes between baseline and month 6
in the test and control groups were 1.5 and 1.8 mm, respec-
tively (NS between groups). BOP in both groups decreased
from about 80 to 40 %. At 4 and 12 weeks, lower counts of
the following bacteria were found in the test group (site level):
Fusobacterium species, Parvimonas micra, Pseudomonas
aeruginosa, Staphylococcus aureus, Tannerella forsythia,
Treponema denticola, and a composite load of nine pathogens
(p<0.001). At week 26, subjects receiving local antibiotics
had a lower prevalence at tested sites for Fusobacterium
nucleatum sp. polymorphum, Fusobacterium periodonticum,
P. micra, and T. denticola.
Conclusions At 26 weeks, treatment with or without piper-
acillin/tazobactam resulted in similar BOP and PPD
improvements. At week 26 and at the subject level, the
prevalence of 4/74 pathogens was found at lower counts in
the group receiving local antibiotics.
Clinical relevance Administration of piperacillin/tazobac-
tam reduces the prevalence of Fusobacterium, P. micra,
and T. denticola to a greater extent than debridement alone
but with no short-term differences in PPD or BOP.
Keywords Periodontitis . Debridement . Local antibiotics .
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Introduction
The routine initial treatment of both chronic and aggressive
periodontitis includes supra- and subgingival debridement
with the objective to remove or at least reduce the infectious
burden such that clinical evidence of inflammation is re-
duced to a clinically acceptable level. The literature on
short- and long-term results of nonsurgical mechanical peri-
odontal therapies is extensive (i.e., [1–7]). Supportive peri-
odontal therapy is considered as critical in maintaining
initial reductions of the subgingival microbiota [8]. Data
suggest that comprehensive periodontal debridement can
achieve important reductions of bacterial counts that may
last for up to 8 months after initial treatment [9]. The
progression of site-specific periodontitis can be predicted
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by monitoring counts of bacteria associated with periodon-
titis [10]. It is also known that subgingival debridement of
root surfaces cannot effectively eliminate all bacteria and
some bacteria may also be present within the dentin layer
[11]. Although treatment often results in an immediate re-
duction of bacterial counts, recolonization has been reported
shortly after therapy [12].
Most studies on microbiological changes following the
administration of local antibiotics have focused on peri-
odontal site-based changes. This has been consistent with
a perception of a site-specific periodontal disease progres-
sion and that site-specific disease progression appears to
occur in clusters of patients [13–17].
Recent studies have also demonstrated that the microbial
content of the periodontal pocket is a determinant of gene
expression in the gingival tissues and this controls the
differential ability of periodontal species to elicit a local
host response [18]. Thus, genetic factors may explain why
periodontitis-susceptible subjects carry a specific pathogen-
ic microbiota in their periodontal pockets. This concept is
consistent with findings that within a periodontitis-
susceptible patient, the presence of many bacterial species
is similar within different sites of a patient with similar
probing pocket depths (PPDs) [19].
Both systemic and local antibiotics have been advocated
as adjunct antimicrobial therapies. Chronic periodontitis
often presents with deep periodontal pockets at a limited
number of sites. Therefore, the administration of local anti-
biotics with a high local concentration, and in combination
with debridement, may be more effective in the manage-
ment of localized periodontal infections than treatment with
debridement alone. Recent studies have documented the
positive effects of using systemic antibiotics to control the
periodontal infection in combination with nonsurgical peri-
odontal therapy [20–23].
Management of “refractory periodontitis”with reduction of
bacteria is also possible by using a combination of a local
antibiotic and subgingival debridement [24]. Others have
shown that local administration of doxycycline in periodontal
pockets of subjects with a smoking habit results in a signifi-
cantly greater reduction in the levels of Porphyromonas
gingivalis in comparison to debridement alone [25]. Recent
studies have, however, also shown that the combined use of
local administration of doxycycline and debridement of
molars with furcation involvement failed to show a significant
difference in vertical probing pocket depth up to 12 months
after treatment and in comparison to local debridement alone
[26]. A difference in horizontal furcation probing depth to the
benefit of drug administration was found [26].
Data suggest that treatment with minocycline HCl micro-
spheres as an adjunct treatment to debridement alone results
in a greater reduction in the levels of P. gingivalis, Tanner-
ella forsythia, and Treponema denticola in combination than
by debridement alone [27–30]. Other studies have, however,
shown that slow release of local antibiotics may not provide
sustainable control of the subgingival microbiota and may not
be different from that of subgingival debridement alone [31,
32]. Thus, probing pocket depth reduction correlated signifi-
cantly with a decrease in the numbers and proportions of red
complex bacteria 30 days after administration [31]. The other
study [32] showed that controlled release of doxycycline did
not significantly suppress several subgingival pathogenic
microorganisms and the authors concluded that this treatment
did not seem to possess no distinct advantage over broad
spectra, safe and inexpensive antiseptics and that the rationale
for its employment in periodontal therapy remains unclear
[32]. In one study using a 14 % doxycycline gel applied
subgingivally at furcation sites following supportive peri-
odontal therapy, the results showed that when applied only
once at baseline, the administration failed to reduce the fre-
quency of the need for re-instrumentation at furcation sites
during supportive therapy for a period of 12 months [26]. In
the most recent study on topical administration of doxycycline
at periodontal sites in subjects with therapy-resistant peri-
odontal pockets, the added use of doxycycline yielded on
average 0.1 mm more reduction in probing pocket depth than
supportive therapy alone at 3 months [33]. At 26 weeks, this
study failed to demonstrate better odds of improved periodon-
tal conditions if treatment included the antibiotic or not [33].
This is consistent with the findings by others using locally
administered doxycycline and that the benefits did not remain
beyond 3 months [34]. The long-term clinical value of adjunct
local antibiotics has been questioned [35, 36].
Thus, local administration of either metronidazole, tet-
racycline, doxycycline, or minocycline adjunct to support-
ive periodontal therapy may not provide additional
significant benefits in regard to probing depth reduction
or gain in clinical attachment compared to results obtained
by mechanical debridement alone [35]. Recent data sug-
gest that treatment with local administration with azithro-
mycin in a gel preparation may provide some clinical
benefits over scaling and root planning alone [37]. The
microbiological impact of such local antibiotic therapy
remains unclear. Some of the tested local antibiotics are
no longer available on the market.
Quorum sensing and plasmid transfer may inhibit efforts
with both systemic and local antibiotics [38, 39]. Data
suggest that piperacillin/tazobactam appears to be effective
against infections by gram-negative anaerobes [40, 41].
Antibiotic resistance to piperacillin/tazobactam seems to be
less than to that to amoxicillin/clavulanic acid [42]. Piper-
acillin/tazobactam also appears to be effective against Pseu-
domonas aeruginosa [43, 44]. P. aeruginosa is known to be
a key pathogen in transmitting antibiotic resistance through
plasmid transfer in biofilms [45, 46]. P. aeruginosa has been
identified in subjects with periodontitis [47, 48]. Therefore,
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control of P. aeruginosa infection in periodontal pockets
may be of importance to enhance the effects of local antibi-
otic administration. Currently, there are no studies available
assessing the effects on P. aeruginosa by local periodontal
administration of antibiotics.
The objective of the present randomized clinical study
was to assess the efficacy of local treatment with piperacil-
lin/tazobactam in conjunction with subgingival debridement
of periodontal pockets in comparison to local debridement
alone using 26-week results as the study endpoint. We tested
the null hypothesis that there are neither microbiological nor
clinical differences in the treatment outcomes between the
two study arms.
Materials and methods
The Ethics Committee at the University of Bern, Switzer-
land (Kantonale Ethik Kommission, Bern, Switzerland)
approved the study. The study was conducted between
2007 and 2010. All participating subjects signed an in-
formed consent. The flow chart for the study is presented
in Fig. 1.
Exclusion criteria
Subjects were excluded
1. If they had received periodontal therapy within the
preceding 6 months
2. If they had been treated with systemic or local anti-
biotics within the preceding 6 months
3. If they were allergic to piperacillin/tazobactam or
penicillin
4. If they were using anti-inflammatory medications or
medications known to cause gingival overgrowth
Inclusion criteria
Subjects were included
1. If they were 18 years of age or older
2. If they had four periodontal non-adjacent sites with a
PPD≥5 mm requiring therapy
3. If they had a diagnosis of chronic periodontitis
Periofilm T®/Asbacare Clinic® (Medirel AS, Agno,
Switzerland) is an antibiotic formulation (European Union
Class III drug) which contains piperacillin and tazobactam
in a formulation suitable for the treatment of periodontitis.
Periofilm T® contains a powder (sodium piperacillin
100 mg, sodium tazobactam 12.5 mg) and a liquid (amino-
alkyl-methacrylate copolymer, ammonium methacrylate co-
polymer, ethanol 95 %, and purified water). The liquid and
powder are mixed immediately before administration with a
supplied syringe.
Clinical measurements and treatment procedures
Subjects were allocated to the treatment group through ran-
domization using the PASW, statistics 18.0 software (IBM/
SPSS, Armonk, NY, USA). Subjects were given coded numb-
ers and then through the software program allocated to either
the test group or control group. Study subjects and therapist
were strictly instructed not to inform the examiner if they had
received treatment with the test drug or not. The clinical
examiner had no access to dental records and was not present
in the clinic when initial treatment or administration of anti-
biotics was performed. The allocation to the intervention
group was not revealed until the data set had been locked.
Bacterial samples were collected at the four selected sites from
which clinical data were collected. The same brand of peri-
odontal probes with 1-2-3-5-7-8-9-10 mm markings (SE4
Pocket probe, Deppeler SA, Rolle, Switzerland) was used to
measure PPD at six sites per tooth. Bleeding on probing
(BOP) of the pockets was defined approximately 10 s after
the measurement of PPD. Only non-adjacent sites from dif-
ferent teeth were studied.
Each subject provided four teeth with a PPD≥5 mm, and
these teeth were included in the study and treated with de-
bridement as deemed necessary with hand instruments and/or
ultrasound. The treatment was performed without time
restrains and continued until the clinician was convinced that
subgingival plaque and calculus had been removed at all the
selected test teeth and neighboring teeth. In subjects withmore
than four sites presenting with a PPD≥5 mm, the four sites
with the deepest PPD were chosen with consideration to risk
for saliva contamination when performing bacterial sampling.
Thus, if a test tooth had more than one site with the same
(deepest) PPD, a buccal and preferably a mesio-buccal site
was chosen. Third molars were excluded. In addition, no site
represented sites associated with furcation involvement. All
teeth were treated with nonsurgical debridement according to
clinical protocol. During the study period, systemic antibiotics
were not prescribed.
Oral hygiene instructions and information about the eti-
ology of periodontitis and various treatment options were
given to each subject prior to the enrollment in the study and
before the initial therapy was given. Following the comple-
tion of this therapy, the selected test teeth were then treated
with the adjunct local antibiotics according to what study
group the subject had been assigned to by computer-based
randomization. The assignment to study group was not
given until the debridement had been completed.
The local antibiotic drug was administered by a clinician
who was unaware of the randomization schedule and other-
wise also not associated with the study. The administration
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of the local antibiotics was performed circumferentially in
the pockets of the selected teeth. No additional treatment
was performed before study endpoint at month 6. Subjects
were given individualized post-treatment oral hygiene
guidelines as required by routine clinical protocol at weeks
1, 2, 4, and 12.
Microbiological sampling
All microbiological samples were taken before probing
pocket depth assessments had been performed. The se-
lected sites representing the deepest non-adjacent sites
within the subject had been defined at a previous visit.
GCF was collected with sterile endodontic paper points
(absorbent paper points size 50, Dentsply/Maillefer, Bal-
laigues, Switzerland). The paper points remained in situ
for 15 s and were then placed in dry Eppendorf tubes
(1.5 ml natural flat cap microcentrifuge tubes, Starlab,
Ahrensburg, Germany). Bacterial samples were taken
before treatment and at 2, 4, 12, and 26 weeks after
intervention.
Analysis of subgingival bacterial samples
The vials were stored at −20 °C and processed after a standard
storage period of 3 months. To each sample, 0.15 ml TE
(10 mM Tris–HCl, 1 mM EDTA, pH 7.6) and 0.5 ml NaOH
were added. All samples were analyzed by checkerboard
DNA-DNA hybridization technique. The 74 species assessed
are presented in Table 1. The checkerboard DNA-DNA hy-
bridization was performed as described elsewhere [48, 49].
Briefly, bacterial DNA was extracted, concentrated on nylon
membranes (Roche Diagnostics GmbH, Mannheim, Ger-
many), and fixed by cross-linking using ultraviolet light
(Stratalinker 1800, Stratagene, La Jolla, CA, USA). The mem-
branes with fixed DNA were placed in a Miniblotter 45
(Immunetics, Cambridge, MA, USA). Signals were detected
by using the Storm Fluor-Imager (Storm 840, Amersham
Fig. 1 Consort flow chart
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Biosciences, Piscataway, NJ, USA)with a setup of 200μmand
600 V. The digitized information was analyzed by a software
program (ImageQuant, Amersham Pharmacia), allowing com-
parisons of the density of the 19 sample lanes against the two
standard lanes (105 or 106 cells). Signals were converted to
absolute counts by comparisons with these standards [34].
Statistical methods
We assumed at 25% difference in the proportion of positive test
results at study sites for P. gingivalis (15 %/40 %) at 26 weeks
after intervention. Using the four sites in 18 subjects from each
group and anticipating that two subjects in each group would
Table 1 Reference bacteria strains included in the DNA-DNA checkerboard analysis
Species Collection Species Collection
Actinomyces israelii ATCC 12102 Lactobacillus jensenii GUH 160339
Actinomyces naeslundii (type I + II) ATCC 43146 Lactobacillus vaginalis GUH 078092
Actinomyces neuii GUH 550898 Leptotrichia buccalis ATCC14201
Actinomyces odontolyticus ATCC 17929 Mobiluncis curtisii GUH 070927
Aggregatibacter actinomycetemcomitans (a) ATCC29523 Mobiluncus mulieris GUH 070926
Aggregatibacter actinomycetemcomitans (Y4) ATCC 43718 Neisseria mucosa ATCC 33270
Aerococcus christensenii GUH 070938 Parvimonas micra ATCC 19696
Aanaerococcus vaginalis GUH 290486 Peptoniphilus sp. GUH 55097
Atopbium parvulum GUH 160323 Porphyromonas endodontalis ATCC 35406
Atopobium vaginae GUH 010535 Porphyromonas gingivalis ATCC 33277
Bacteroides ureolyticus GUH 080189 Prevotella bivia GUH 450429
Bifidobacterium biavatii GUH 071026 Prevotella disiens GUH 190184
Bifidobacterium bifidum GUH 070962 Prevotella intermedia ATCC 25611
Bifidobacterium breve GUH 080484 Prevotella melaninogenica ATCC 25845
Bifidobacterioum longum GUH 180689 Propionibacterium acnes ATCC 11727/2
Campyobacter gracilis ATCC 33236 Proteus mirabilis GUH 07092
Campylobacter rectus ATCC 33286 Pseudomonas aeruginosa DSMZ 50071
Campylovacter showae ATCC 51146 Selenomonas noxia ATCC 43541
Capnocytophaga gingivalis ATCC 33612 Staphylococcus anaerobius DSMZ 20714
Capnocytophaga ochraceae ATCC 335945 Staphylococcus aureus ATCC 25923
Capnocytophaga sputigena ASTCC 33612 Staphylococcus aureus (yellow) GUH 070921
Corynebacterium nigricans GUH450453 Staphylococcus aureus (white) GUH 070922
Corynerbacterium aurimucosum GUH 071035 Staphylococcus epidermis GUH 130381
Dialister sp. GUH 071045 Staphylococcus haemolyticus DSMZ 20263
Escherichia coli GUH 070903 Streptococcus agalactiae GUH 230282
Eikenella corrodens ATCC 23834 Streptococcus anginosus ATCC 33397
Enterococcus faecalis GUH 170812 Streptococcus constellatus ATCC 27823
Enterococcus faecalis ATCC 29212 Streptococcus gordonii ATCC 10558
Fusobacterium nucleatum
nucleatum
ATCC 25586 Streptococcus intermedius ATCC 27335
Fusobacterium nucleatum polymorphum ATCC 10953 Streptococcus mitis ATCC 49456
Fusobacterium nucleatum naviforme ATCC 49256 Streptococcus oralis ATCC 35037
Fusobacterium periodonticum ATCC 33693 Streptococcus pneumoniae DSMZ 11866
Gardnerella vaginalis GUH 080585 Streptococcus sanguinis ATCC 10556
Haemophilus influenzae ATCC 49247 Streptococcus mutans ATCC 25175
Helicobacter pylori ATCC 43504 Tannerella forsythia ATCC 43037
Lactobacillus acidophilus ATCC 11975 Treponema denticola ATCC 35405
Lactobacillus crispatus GUH 160342 Treponema socranskii D40DR2
Lactobacillus gasseri GUH 17085 Varibaculum cambriense GUH 070917
Lactobacillus iners GUH 160334 Veillonella parvula ATCC 10790
ATCC American Type Culture Collection; D sample from Forsyth Institute, Boston, MA, USA; GUH Ghent University Hospital Collection, Ghent,
Belgium
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not complete the study (n064 per group), the power would be
88 %. The Kolmogorov–Smirnov test was used to assess
whether the data set had a normal distribution pattern or not.
Independent t tests (equal variance not assumed) and Mann–
Whitney U tests to screen for bacteria with significant differ-
ences in bacterial counts were performed. Subject-based bacte-
rial counts were calculated based on the number of sites with
bacteria present at week 26. General linear model multivariate
ANOVA using Sidak’s correction for multiple observations and
with smoking, age, and gender as covariates was used to assess
differences by bacterial presence at the subject level. The
PASW, statistics 18.0 software for MAC OS X version 10.6.7
was used for the analysis of the data (IBM SPSS).
Results
A total of four subjects were lost to follow-up before the first
visit after the intervention. Due to the fact that they never
returned for the bacterial samplings or clinical follow-up, no
data after enrollment could be collected from these four subjects
in the control group. The data from these subjects were exclud-
ed from the analysis. Data were studied in 18 subjects (4/18,
22.2 % smokers) from the test group including 72 test sites and
in 14 (2/14, 14.3 % smokers) subjects from the control group
including 56 test sites. The mean age of the study population
was 52.1 years (SD±10.3) in both groups and thus with no
statistically significant difference by study groups. During the
study period, no adverse events were identified.
Clinical data: probing pocket depth and bleeding on probing
at sites from which bacterial samples were taken
The study included 41.0 % incisors and cuspids, 20.1 %
premolars, and 38.8 % molars. Baseline overall PPD values
at sites from which bacterial samples were collected varied
between 5 and 11 mm (overall mean 6.8 mm, SD±1.3 mm).
At baseline, the mean PPD in the control and test groups
were 7.0 mm (SD±1.2) and 6.8 mm (SD±1.3), respectively
(NS). At week 26, the corresponding PPD values were
5.2 mm (SD±1.5) and 5.1 (SD±1.4), respectively (NS). At
baseline, all PPD values were >5 mm. At week 26, 42.9 %
of the sites in the control group had a PPD value >5 mm,
whereas 35.5 % of the sites in the test group had a PPD
value >5mm. Themean difference (decrease) in PPD between
baseline and week 26 in the control group was 1.8 mm
(SE±0.3; 95 % CI 1.2, 2.3; p<0.001). The mean difference
(decrease) in PPD between baseline and week 26 in the test
group was 1.5 mm (SE±0.2; 95%CI 1.1, 2.0; p<0.001). Both
at baseline and at week 26, general linear model univariate
analysis with smoking status and sample site as covariates,
statistical analysis failed to demonstrate study group differ-
ences in PPD values both at baseline and at week 26.
At baseline and at sites from which bacterial samples
were taken, BOP was present at 85.1 % in the control group
and at 82.1 % in the test group (NS). At week 26, BOP was
found at 44.9 % in the control group and at 38.2 % sites in
the test group. Statistical analysis failed to demonstrate
group differences in BOP scores at either time point.
Considering smoking status, statistical analysis failed to
demonstrate differences in PPD values. At baseline, the
mean difference in PPD by smoking status was 0.3 mm
(SE±0.3; 95 % CI −0.2, 0.8; p00.24). The mean PPDs in
smokers and nonsmokers at baseline were 6.5 mm (SD±1.3)
and 6.8 mm (SD±1.3) (p00.24). The mean PPDs in smok-
ers and nonsmokers at week 26 were 4.9 mm (SD±1.2) and
5.2 mm (SD±1.5), respectively (p00.38).
Microbiology
Analysis by Kolmogorov–Smirnov test failed to identify a
normal distribution pattern by bacterial counts. Based on the
screening of the 74 bacterial species included in the check-
erboard DNA-DNA hybridization method, the 15 species
with the highest prevalence rates at baseline and 2, 4, 12,
and 26 weeks after treatment in the test and control groups
were identified. The mean values of each of these species by
study group are presented in descending order (Figs. 2a, b;
3a, b; 4a, b; 5a, b; and 6a, b). It is noteworthy that at
baseline, the mean values of these bacteria were similar by
study group. With few exceptions, the same bacteria were
identified including Aggregatibacter actinomycetemcomi-
tans (Y4), Fusobacterium nucleatum spp. naviforme, Fuso-
bacterium nucleatum spp. nucleatum, Parvimonas micra, P.
gingivalis, P. aeruginosa, and T. forsythia. The total count of
a composite pathogen group including these species and
also including T. denticola and Staphylococcus aureus was
computed. The load of this composite bacterial group was
further assessed (see below).
At 2, 4, and 12 weeks, it is obvious that shifts in the
prevalence ranking order of species had occurred in both study
groups. Consistently, A. actinomycetemcomitans (Y4) was
present at much higher levels in the control group. Other
species were also present at higher counts in the control group.
At 26 weeks, most differences between the two groups had
disappeared. The prevalence rates (percent) at the bacterial
level ≥1.0×105 cells for each of the bacteria included in the
composite pathogen group are shown in Table 2. In the control
group and at 4 weeks, a relevant decrease in the prevalence
rate based on the ≥1.0×105 cells detection level was not found
for any of the species. At week 4 in the test group, P. gingi-
valis, P. aeruginosa, and T. forsythia decreased ≥20 % in
detection prevalence rates. At 26 weeks, the decrease
remained in the test group for P. aeruginosa and T. forsythia.
At baseline, smokers had a higher bacterial count of T.
forsythia than nonsmokers (p00.008). This difference did
1650 Clin Oral Invest (2013) 17:1645–1660
not exist at week 26. Analysis by general linear model multi-
variate analysis with smoking status, and sample site as cova-
riates, with the above listed species, and the composite
bacterial counts as dependent variables and adjustment for
multiple comparisons by Sidak correction for multiple obser-
vation found significantly higher bacterial counts in the con-
trol group at baseline for the following species: P. micra, S.
aureus (p<0.01), and with the largest difference for T. denti-
cola (mean difference −1.3×105 cells; 95 % CI −2.1, −0.4×
105; p00.005). The corresponding results from the analysis at
weeks 2, 4, 12, and 24 are presented in Table 3. Thus,
specifically at weeks 4 and 12, significantly lower counts of
the following bacteria were found in the test group: A. actino-
mycetemcomitans (Y4), F. nucleatum species, P. micra, P.
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gingivalis, P. aeruginosa, S. aureus, and T. denticola were
found in the test group. At week 26, only F. nucleatum spp.
polymorphum, F. periodonticum, P. micra, P. aeruginosa, and
T. denticola were found at lower counts in the test group.
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Subject-based microbiological analysis
The five microbiological species that were found to differ by
the site-specific analysis were further investigated. At baseline
and at week 26, the number of sites that were defined as being
positive for these five species identified as being present at a
bacterial level ≥1.0×105 cells (primary detection level for the
checkerboard method) were provided a subject-based number.
Analysis by general linear model multivariate ANOVA in-
cluding smoking habit, subject age, and gender as covariates,
and using Sidak’s correction for multiple observations, the
analysis failed to identify baseline differences in a number of
positive sites for the five species studied. At week 26, how-
ever, the same analysis identified that significantly fewer
positive sites were found in subjects who had been treated
with the antibiotics for the following species: T. denticola
(p<0.001), F. nucleatum spp. polymorphum (p00.001), P.
micra (p00.006), and F. periodonticum (p00.013).
Discussion
There are currently no other clinical data on the efficacy to
reduce bacterial counts in periodontal pockets by a single
administration of piperacillin/tazobactam in subjects with
moderate to advanced periodontitis. P. gingivalis was cho-
sen as the target pathogen and as the primary outcome
measure because it has been studied extensively in associa-
tion with periodontitis [8, 23–25, 30, 35, 37]. Several other
bacterial species demonstrated a greater susceptibility to the
intervention in the test group and this effect remained also at
week 26 for some species but not for P. gingivalis, T.
forsythia, or A. actinomycetemcomitans.
The limitation of the present study is that the control subjects
were not treated with a placebo drug administration. Neverthe-
less, the clinical examiner and the laboratory staff members
were blinded to the protocol assignment to control for bias.
Another limitation is that the evidence of bacterial changes
following periodontal interventions from other studies does
not easily provide information that can be utilized for statistical
power analysis. Thus, we assumed based on our laboratory
experiences that a 20–25 % difference could be anticipated. A
decrease amounting to approximately 20–25%was obtained in
the test group at weeks 2 and 4 for P. gingivalis and P.
aeruginosa. At week 26, this remained the case for P. aerugi-
nosa, suggesting that the administration of piperacillin/tazobac-
tam has a relevant effect but limited to the control of P.
aeruginosa subgingival colonization. One of the reasons why
the reduction in bacterial counts was limited may be the result
of less than optimal control of gingival inflammation as noticed
by the rather high proportion of BOP at study endpoint.
The decreases in PPD and BOP obtained in the present
study are consistent with the other studies on subgingival
debridement not using antibiotics [1–7]. The extent of PPD
reduction and decrease in BOP in the present study suggested a
clinical effective outcome of therapy provided in both groups.
Furthermore, the extent of PPD reduction in both study groups
in the present study was comparable, or greater to PPD reduc-
tions after combined local debridement and local antibiotics in
other studies [30, 50]. In the present study, we treated subjects
who were diagnosed with moderate to severe chronic perio-
dontitis, and we only assessed interproximal conditions. In
other similar studies, periodontal sites with more shallow PPDs
have been studied [18, 21, 38]. It is well known that the
reduction of PPD in the range of 1.5 to 2.0 mm can be obtained
by debridement alone in deep periodontal pockets [1–3]. The
extent of possible probing depth reduction may also be limited
by anatomical factors such as the extent and topography of
alveolar bone loss and attachment loss.
Some data have shown that local administration of doxycy-
cline or minocycline in addition to debridement in subjects who
smoke results in greater reduction in the frequency of P.
Table 2 Distributions of selected bacteria at different sample times in the test and control groups by the detection level for a positive test result
(≥×1.05 bacterial cells) that is the standard detection level for the checkerboard DNA-DNA hybridization method
Composite species Baseline 2 weeks 4 weeks 12 weeks 24 weeks
Test Control Test Control Test Control Test Control Test Control
A. actinomycetemcomitans 88.0 80.4 65.2 78.3 71.4 83.0 71.1 76.0 71.6 73.0
F. nucleatum naviforme 54.3 70.4 44.9 60.9 38.1 55.3 47.0 68.0 49.4 59.5
P. micra 51.1 66.7 28.1 63.0 34.5 68.1 61.0 64.5 39.5 63.2
P. gingivalis 38.0 58.5 13.5 21.7 16.7 29.8 16.9 30.0 24.7 29.7
P. aeruginosa 43.7 61.5 24.5 61.8 13.4 74.3 26.2 61.5 17.8 50.0
S. aureus 28.3 51.0 14.6 52.2 15.1 53.2 27.7 52.0 23.5 35.1
T. forsythia 68.5 76.5 42.7 67.4 41.7 61.7 41.0 60.0 48.1 57.8
T. denticola 47.8 68.6 30.3 58.7 32.1 66.0 37.3 50.0 37.0 73.0
A. actinomycetemcomitans is represented by the Y4 reference strain
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gingivalis [22, 25]. In the present study, smoking did not seem
to have an impact on the study outcomes neither on PPD nor
BOP changes or microbiological changes. This may be
explained by the low prevalence of smokers in the study.
Smoking, subject age, and gender were included as covariates
in the subject-based analysis but did not significantly influence
the results.
Although subject-based factors must be considered, it is
generally perceived that chronic periodontitis is tooth/site-
specific [13–17]. In the present study, each subject contrib-
uted four individual test sites representing the sites with the
most advanced periodontitis. Thus, no subject was overrep-
resented providing more data than any other subject.
Several studies have used site-based analysis and performed
microbiological sampling only from mesio-buccal surfaces
[8, 22, 24, 50–56]. There appears to be a defined order in
bacterial species succession in early supragingival and sub-
gingival biofilm redevelopment after professional cleaning.
The site-specific development of periodontitis may be the
result of the symbiotic effects due to co-aggregation in
subgingival biofilms including P. gingivalis, T. denticola,
and T. forsythia [53].
Thus, the presence and counts of P. gingivalis, T. denticola,
and T. forsythia may suggest the stability of periodontal con-
ditions at individual sites at teeth. The observations that local
treatment with antibiotics can reduce the counts of these
Table 3 Microbiological differences by study groups after intervention at weeks 2, 4, 12, and 26
Time point Species Mean differences×105 cells 95 % CI×105 cells p values
Week 2 A. actinomycetemcomitans Y4 8.8 1.6, 16.0 0.001
F. nucleatum naviforme 1.3 0.5, 2.1 0.002
F. nucleatum polymorphum 1.3 0.5, 2.1 0.002
F. periodonticum 0.9 0.1, 1.7 0.02
S. aureus 1.0 0.6, 1.4 0.001
T. denticola 0.7 0.4, 1.1 0.001
Composite bacteria 12.3 0.4, 24.1 0.042
Week 4 A. actinomycetemcomitans Y4 7.9 2.5, 13.3 0.005
F. nucleatum naviforme 2.2 1.0, 3.4 0.000
F. nucleatum polymorphum 1.7 1.0, 2.5 0.000
F. periodonticum 1.3 0.7, 1.9 0.000
P. micra 1.8 1.0, 2.5 0.000
P. gingivalis 1.1 0.3, 1.9 0.006
P. aeruginosa 1.5 1.0, 2.1 0.000
S. aureus 1.0 0.7, 1.2 0.000
T. forsythia 4.5 0.8, 8.2 0.017
T. denticola 1.3 0.7, 1.9 0.000
Composite bacteria 21.3 12.1, 30.5 0.000
Week 12 F. nucleatum naviforme 2.2 1.0, 3.4 0.001
F. nucleatum nucleatum 1.4 0.6, 2.3 0.001
F. nucleatum polymorphum 1.9 1.3, 2.5 0.000
F. periodonticum 1.3 0.8, 1.8 0.000
P. micra 2.1 1.2, 3.0 0.000
P. gingivalis 0.4 0.1, 1.8 0.032
P. aeruginosa 1.1 0.5, 1.6 0.000
S. aureus 1.4 0.8, 1.9 0.000
T. forsythia 5.6 1.5, 9.8 0.009
T. denticola 1.2 0.6, 1.8 0.000
Composite bacteria 18.3 9.8, 26.8 0.000
Week 26 F. nucleatum polymorphum 1.1 0.1, 1.9 0.029
F. periodonticum 0.8 0.1, 1.5 0.019
P. micra 1.2 0.3, 2.0 0.008
P. aeruginosa 0.5 0.1, 1.0 0.046
T. denticola 0.6 0.3, 1.0 0.002
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species are important [31, 50]. In the present study, the adjunct
administration of piperacillin/tazobactam resulted in more
reduction of not only P. gingivalis, T. denticola, and T. for-
sythia but also other species associated with co-aggregation in
biofilms (i.e., F. nucleatum) and other bacteria that are asso-
ciated with several diseases (P. aeruginosa and S. aureus) and
identified not only in periodontitis but also in subjects with
peri-implantitis [48, 57–60].
It should also be noticed that the changes in bacterial
counts over time were not consistently the same by different
species. This may reflect the fluctuating state of bacterial
growth and changes in the development of biofilms at
different sites from which samples were taken. To some
extent, it may also reflect measurement errors in sampling
which might be the greatest error and by the laboratory
procedures. The fact that the bacterial counts of P. aerugi-
nosa and S. aureus at study endpoint did not differ by study
group could be viewed as a positive finding in that these two
species did not show evidence in counts that might suggest
antibiotic resistance or other advantages by the medication.
The present study identified that without the use of the
antibiotic, limited changes were found after debridement
among the target bacteria. Recolonization of bacteria also oc-
curred in the test group, and this is consistent with other studies
[35]. Recolonization of bacteria following periodontal surgery
in newly established shallow periodontal pockets also occurs
soon after surgery [60]. This is consistent with the general
concept that mechanical elimination of bacteria in a biofilm is
not possible. Oral bacteria in biofilm comprise a complex
community depending on the interface between the host and
the microbial community as a whole [61]. Elimination of bac-
teria associated with periodontitis may therefore not be possible
using local administration of antibiotics [32]. In addition to
plasmid transfer and antibiotic resistance, there is a mechanical
protective glycolax layer that protects the biofilm and prevents
penetration of antibiotics, and debridement may not effectively
eliminate this glycolax in deep periodontal pockets.
In the present study, high counts of P. aeruginosa were
found in the post-treatment findings in subjects in the con-
trol group. While piperacillin/tazobactam appears to be ef-
fective against P. aeruginosa [43, 44], this may explain why
lower counts of P. aeruginosa were found in the test groups.
In the present study, high counts of A. actinomycetemcomi-
tans were found both at baseline and especially throughout
the study in the control group, suggesting that subgingival
debridement alone cannot significantly reduce or eliminate
this microorganism. This observation is consistent with
other studies suggesting that A. actinomycetemcomitans is
difficult to manage through mechanical debridement alone
[32, 62, 63]. The reduction of A. actinomycetemcomitans
was, however, also limited in the test group. Although
bacteria commonly viewed as putative pathogens in perio-
dontitis, i.e., T. forsythia and P. gingivalis, were similarly
affected by study procedures, the pathogenic capacities of P.
micra, Fusobacterium species, and T. denticola should not
be minimized. The lower prevalence of these species in the
test group should be considered as having a beneficial
impact on periodontal status. There are many studies to
suggest that P. micra, Fusobacterium species, and T. denti-
cola are present at high counts in cases with periodontitis
(i.e., [8–10]).
In conclusion, the present study identified similar improve-
ments in clinical periodontal outcomes at week 26 in subjects
treated with nonsurgical debridement with or without a one-
time administration of a local antibiotic (piperacillin/tazobac-
tam). At the subject level, the local antibiotic therapy controlled
the colonization of T. denticola, F. nucleatum polymorphum, F.
periodonticum, and P. micra.
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